2025 Q4 -tulosraportti
Vain PDF
76 päivää sitten
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 | - | - | ||
| 2 000 | - | - | ||
| 347 | - | - | ||
| 1 153 | - | - | ||
| 847 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·17 t sittenPerhaps this could be significant for Induct in the long term: AstraZeneca has received significant US regulatory approvals for two of its key medicines: Breztri for asthma treatment and Saphnelo for self-administration in systemic lupus erythematosus (SLE). These approvals expand treatment options and convenience for patients. The company is also preparing to publish its first-quarter report, while analysts maintain a positive view on the stock. AstraZeneca's Breztri Aerosphere received US FDA approval for maintenance treatment of asthma in adult and pediatric patients aged 12 years and older, marking its second indication after COPD. The US FDA approved Saphnelo (anifrolumab) for self-administration via a once-weekly autoinjector (Saphnelo Pen) for adult patients with systemic lupus erythematosus (SLE), improving patient convenience and accessibility.
·1 päivä sittenSlides from the presentation: https://www.healthinnovationoxford.org/wp-content/uploads/2026/04/RTP-Launch-Webinar-23-April-slides-1.pdf recording: https://youtu.be/ZwawwQR0c1c
·1 päivä sittenWho is constantly selling? Is there anyone with an endless number of shares? Is anyone benefiting from selling cheap? Anyone following the largest positions and can say something? This is the least shareholder-friendly company I have owned, considering the lack of info and marketing. It's going incredibly slow from the company's side, which still has yet to deliver on expectations…
·15 t sittenAs several have mentioned previously, it is likely Kimpot AS and NPP Capital who have sold off large stakes. Whether this is the case now is not known, as I don't have the latest figures.
·2 päivää sitten@Gold-end The RTP meeting was a closed meeting between the financing parties (The Authorities, NHS, AZ, GSK, et al.). Perhaps one should interpret 0 info as the negotiations being finished, but not yet announced. If Induct were to announce something now, it would be a breach of insider information rules. And if Induct was out of the dance, or just one among many, the professors (Brown/Crooks) would not have fronted the Induct methodology OPTIMISE so massively at the webinar on April 23rd. OPTIMISE is the name of Induct's specific module in Portsmouth, so the connection is completely direct. Triggers are coming in May, we just have to wait. It looked like rollout wave 1 was 9 regions starting now in May and targeting November 2026. These regions probably cover about 25% of England, so that's no small feat. Then wave 2 comes afterwards with the rest of the country, then COPD is also connected in the RTP rollout. Hull is outside RTP, and that's probably to quickly secure a purely commercial SaaS subscription. Then we get the price in Hull and the volume in RTP. Extra exciting if W1 and W2 are linked together, which is massive for Induct, because then they own the entire patient journey for all asthma, not just severe asthma. Even better if Hull becomes the playground for AZ/Induct to test the COPD module first, so they have the proof ready for wave 2. Possibly the Q1 report on May 13th will be exciting reading.
·2 päivää sitten · Muokattu@Eivloek I find no connection between OPTIMISE and Induct's module in Portsmouth. OPTIMISE seems to be mentioned sporadically throughout the webinar, without any clear link to Portsmouth or severe asthma specifically. Do you have other sources for this?·13 t sittenIn my fantasy world, I think one chooses a clinical model that has proven success first. That OPTIMISE is mentioned under 'COPD only' on certain slides, actually just confirms this. NHS has seen that the model works for asthma (via Portsmouth/Induct) and has now decided that this methodology will eventually be transferred to COPD. The RTP slides explicitly state that they will scale "successful models". Portsmouth is one of the successful models. When other areas give feedback on OPTIMISE, it's because they have now started to implement what Portsmouth has done. Which tool to use comes afterwards. Here, contracts must be signed before they are mentioned. If they are to follow the OPTIMISE recipe to the letter (as RTP requires), they must have a tool that supports the algorithms. As of today, that is what Induct and Porthsmouth have done in recent years.- ·2 päivää sittenHow should one interpret 0 info released from the important meeting, is Induct suddenly one of many potential software suppliers for the same project?2 päivää sitten2 päivää sittenNone of the listed software on the RTP meeting slides has anything to do with Inducts software
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
76 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17 t sittenPerhaps this could be significant for Induct in the long term: AstraZeneca has received significant US regulatory approvals for two of its key medicines: Breztri for asthma treatment and Saphnelo for self-administration in systemic lupus erythematosus (SLE). These approvals expand treatment options and convenience for patients. The company is also preparing to publish its first-quarter report, while analysts maintain a positive view on the stock. AstraZeneca's Breztri Aerosphere received US FDA approval for maintenance treatment of asthma in adult and pediatric patients aged 12 years and older, marking its second indication after COPD. The US FDA approved Saphnelo (anifrolumab) for self-administration via a once-weekly autoinjector (Saphnelo Pen) for adult patients with systemic lupus erythematosus (SLE), improving patient convenience and accessibility.
- ·1 päivä sittenSlides from the presentation: https://www.healthinnovationoxford.org/wp-content/uploads/2026/04/RTP-Launch-Webinar-23-April-slides-1.pdf recording: https://youtu.be/ZwawwQR0c1c
- ·1 päivä sittenWho is constantly selling? Is there anyone with an endless number of shares? Is anyone benefiting from selling cheap? Anyone following the largest positions and can say something? This is the least shareholder-friendly company I have owned, considering the lack of info and marketing. It's going incredibly slow from the company's side, which still has yet to deliver on expectations…·15 t sittenAs several have mentioned previously, it is likely Kimpot AS and NPP Capital who have sold off large stakes. Whether this is the case now is not known, as I don't have the latest figures.
- ·2 päivää sitten@Gold-end The RTP meeting was a closed meeting between the financing parties (The Authorities, NHS, AZ, GSK, et al.). Perhaps one should interpret 0 info as the negotiations being finished, but not yet announced. If Induct were to announce something now, it would be a breach of insider information rules. And if Induct was out of the dance, or just one among many, the professors (Brown/Crooks) would not have fronted the Induct methodology OPTIMISE so massively at the webinar on April 23rd. OPTIMISE is the name of Induct's specific module in Portsmouth, so the connection is completely direct. Triggers are coming in May, we just have to wait. It looked like rollout wave 1 was 9 regions starting now in May and targeting November 2026. These regions probably cover about 25% of England, so that's no small feat. Then wave 2 comes afterwards with the rest of the country, then COPD is also connected in the RTP rollout. Hull is outside RTP, and that's probably to quickly secure a purely commercial SaaS subscription. Then we get the price in Hull and the volume in RTP. Extra exciting if W1 and W2 are linked together, which is massive for Induct, because then they own the entire patient journey for all asthma, not just severe asthma. Even better if Hull becomes the playground for AZ/Induct to test the COPD module first, so they have the proof ready for wave 2. Possibly the Q1 report on May 13th will be exciting reading.·2 päivää sitten · Muokattu@Eivloek I find no connection between OPTIMISE and Induct's module in Portsmouth. OPTIMISE seems to be mentioned sporadically throughout the webinar, without any clear link to Portsmouth or severe asthma specifically. Do you have other sources for this?·13 t sittenIn my fantasy world, I think one chooses a clinical model that has proven success first. That OPTIMISE is mentioned under 'COPD only' on certain slides, actually just confirms this. NHS has seen that the model works for asthma (via Portsmouth/Induct) and has now decided that this methodology will eventually be transferred to COPD. The RTP slides explicitly state that they will scale "successful models". Portsmouth is one of the successful models. When other areas give feedback on OPTIMISE, it's because they have now started to implement what Portsmouth has done. Which tool to use comes afterwards. Here, contracts must be signed before they are mentioned. If they are to follow the OPTIMISE recipe to the letter (as RTP requires), they must have a tool that supports the algorithms. As of today, that is what Induct and Porthsmouth have done in recent years.
- ·2 päivää sittenHow should one interpret 0 info released from the important meeting, is Induct suddenly one of many potential software suppliers for the same project?2 päivää sitten2 päivää sittenNone of the listed software on the RTP meeting slides has anything to do with Inducts software
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 | - | - | ||
| 2 000 | - | - | ||
| 347 | - | - | ||
| 1 153 | - | - | ||
| 847 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
76 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·17 t sittenPerhaps this could be significant for Induct in the long term: AstraZeneca has received significant US regulatory approvals for two of its key medicines: Breztri for asthma treatment and Saphnelo for self-administration in systemic lupus erythematosus (SLE). These approvals expand treatment options and convenience for patients. The company is also preparing to publish its first-quarter report, while analysts maintain a positive view on the stock. AstraZeneca's Breztri Aerosphere received US FDA approval for maintenance treatment of asthma in adult and pediatric patients aged 12 years and older, marking its second indication after COPD. The US FDA approved Saphnelo (anifrolumab) for self-administration via a once-weekly autoinjector (Saphnelo Pen) for adult patients with systemic lupus erythematosus (SLE), improving patient convenience and accessibility.
- ·1 päivä sittenSlides from the presentation: https://www.healthinnovationoxford.org/wp-content/uploads/2026/04/RTP-Launch-Webinar-23-April-slides-1.pdf recording: https://youtu.be/ZwawwQR0c1c
- ·1 päivä sittenWho is constantly selling? Is there anyone with an endless number of shares? Is anyone benefiting from selling cheap? Anyone following the largest positions and can say something? This is the least shareholder-friendly company I have owned, considering the lack of info and marketing. It's going incredibly slow from the company's side, which still has yet to deliver on expectations…·15 t sittenAs several have mentioned previously, it is likely Kimpot AS and NPP Capital who have sold off large stakes. Whether this is the case now is not known, as I don't have the latest figures.
- ·2 päivää sitten@Gold-end The RTP meeting was a closed meeting between the financing parties (The Authorities, NHS, AZ, GSK, et al.). Perhaps one should interpret 0 info as the negotiations being finished, but not yet announced. If Induct were to announce something now, it would be a breach of insider information rules. And if Induct was out of the dance, or just one among many, the professors (Brown/Crooks) would not have fronted the Induct methodology OPTIMISE so massively at the webinar on April 23rd. OPTIMISE is the name of Induct's specific module in Portsmouth, so the connection is completely direct. Triggers are coming in May, we just have to wait. It looked like rollout wave 1 was 9 regions starting now in May and targeting November 2026. These regions probably cover about 25% of England, so that's no small feat. Then wave 2 comes afterwards with the rest of the country, then COPD is also connected in the RTP rollout. Hull is outside RTP, and that's probably to quickly secure a purely commercial SaaS subscription. Then we get the price in Hull and the volume in RTP. Extra exciting if W1 and W2 are linked together, which is massive for Induct, because then they own the entire patient journey for all asthma, not just severe asthma. Even better if Hull becomes the playground for AZ/Induct to test the COPD module first, so they have the proof ready for wave 2. Possibly the Q1 report on May 13th will be exciting reading.·2 päivää sitten · Muokattu@Eivloek I find no connection between OPTIMISE and Induct's module in Portsmouth. OPTIMISE seems to be mentioned sporadically throughout the webinar, without any clear link to Portsmouth or severe asthma specifically. Do you have other sources for this?·13 t sittenIn my fantasy world, I think one chooses a clinical model that has proven success first. That OPTIMISE is mentioned under 'COPD only' on certain slides, actually just confirms this. NHS has seen that the model works for asthma (via Portsmouth/Induct) and has now decided that this methodology will eventually be transferred to COPD. The RTP slides explicitly state that they will scale "successful models". Portsmouth is one of the successful models. When other areas give feedback on OPTIMISE, it's because they have now started to implement what Portsmouth has done. Which tool to use comes afterwards. Here, contracts must be signed before they are mentioned. If they are to follow the OPTIMISE recipe to the letter (as RTP requires), they must have a tool that supports the algorithms. As of today, that is what Induct and Porthsmouth have done in recent years.
- ·2 päivää sittenHow should one interpret 0 info released from the important meeting, is Induct suddenly one of many potential software suppliers for the same project?2 päivää sitten2 päivää sittenNone of the listed software on the RTP meeting slides has anything to do with Inducts software
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 | - | - | ||
| 2 000 | - | - | ||
| 347 | - | - | ||
| 1 153 | - | - | ||
| 847 | - | - |
Välittäjätilasto
Dataa ei löytynyt